ABCL688

ABCL688 is an early-stage antibody therapeutic candidate being developed by **AbCellera Biologics** for the treatment of autoimmune diseases. The drug is described as an **ion channel- or GPCR-targeted antibody** designed to modulate complex membrane proteins. According to the available information, ABCL688 targets either an ion channel or a G-protein coupled receptor (GPCR), though the specific target has not been publicly disclosed. The antibody is designed to address difficult-to-drug membrane proteins, showcasing AbCellera's AI-driven antibody discovery platform capabilities. As of October 2025, ABCL688 is in IND/CTA-enabling studies (preclinical stage) and has not yet entered clinical trials. The company advanced this candidate into IND-enabling studies in mid-2025, positioning it as part of their autoimmunity-focused pipeline. The development of ABCL688 demonstrates AbCellera's technical capacity to create antibodies against challenging multipass complex membrane proteins that are typically difficult targets for conventional antibody approaches.